Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : EXL01
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Alimentiv
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EXL01 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Crohn Disease.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 15, 2022
Lead Product(s) : EXL01
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Alimentiv
Deal Size : Inapplicable
Deal Type : Inapplicable